EA
TGTX icon

Evolution Advisers’s TG Therapeutics TGTX Stock Holding History

Evolution Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+15
New +$614 ﹤0.01% 825

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Evolution Advisers's TGTX Position: Q2 2026 in Review

Evolution Advisers opened a new position in TG Therapeutics (TGTX) in Q2 2026: 15 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #825 among its holdings.

427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Evolution Advisers held 15 shares of TG Therapeutics worth $0 as of Q2 2026.
  • TG Therapeutics was a new Evolution Advisers position in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #825 holding.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.